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SUMMARY
Objectives: To conduct a systematic review to determine whether there is an
association between metabolic syndrome (MetS) and lower urinary tract symptoms
(LUTS) or overactive bladder (OAB) in women. Methods: We systematically
reviewed English language observational studies on the effect of MetS (or compo-
nent factors) on the presence of OAB or LUTS in women. We searched PubMed,
Web of Science and The Cochrane Library with no date restrictions, checked refer-
ence lists and undertook citation searches in PubMed and Google Scholar. Studies
were assessed for risk of bias. Because of heterogeneity, results were not pooled,
but are reported narratively. Results: Of 27 included studies, only three looked at
the link between MetS and OAB. The rest looked at links between OAB and com-
ponents of MetS such as obesity or insulin resistance (n = 10), between MetS and
urinary symptoms (n = 3) and between urinary symptoms and components of
MetS, such as obesity (n = 14). Evidence is currently limited, but it does suggest
that there may be important links between MetS and OAB and components of
MetS such as obesity. Conclusions: The literature on MetS and OAB or LUTS in
women is limited, and poor quality. However, the evidence available on obesity
appears to support MetS as a contributor and predictor of LUTS in women. Many
of the women with LUTS will be overweight and will have features of the MetS, if
looked for. This provides not only an opportunity to encourage weight loss as an
adjunct to therapy for the OAB symptoms but also a window of opportunity to
address cardiovascular risk factors and prevent future cardiovascular morbidity and
mortality.
Review criteria
Observational studies examining the link between
metabolic syndrome (MetS) (or components of MetS)
and the presence of OAB or LUTS were identified
through database and lateral searches.
Message for the clinic
Both obesity and MetS have been shown to have
complex links with LUTS. It is not known whether
reducing insulin resistance and central obesity-related
chronic inflammation and oxidative stress might
prevent the onset of OAB or improve the outcome of
current treatment. However, identifying women with
MetS who harbour a portfolio of cardiovascular risk
factors does provide an opportunity to address future
cardiovascular risk, and prevent premature morbidity
and mortality; although whether this will have an
effect on the storage component of LUTS is unclear.
The key variables to address are diet and lifestyle,
especially exercise. The investigations should include
a blood pressure recording, BMI and waist
circumference measurement together with a lipid
profile and HbA1c. These results should be
transmitted to the GP for action.
Background
Introduction to overactive bladder
Lower urinary tract symptoms (LUTS) is now
thought of as an umbrella term, encompassing all
disorders of bladder and urethral function (1),
including storage, voiding and postmicturition symp-
toms (2). Storage symptoms are often more stressful
and bothersome than voiding symptoms; especially if
incontinence features as a symptom (3). The preva-
lence of LUTS in women has been found to be high,
with 76% of women aged between 40 and 99 years
reporting that they sometimes had LUTS and 53%
that they often did (4).
The term overactive bladder (OAB) is used to
describe storage symptoms excluding stress
(exertional) urinary incontinence and has been
defined as a symptom complex characterised by uri-
nary urgency, with or without urgency incontinence,
usually with urinary frequency and nocturia (5). Inter-
national population-based studies have reported prev-
alence rates of OAB around 12% (6,7) rising to 17% in
individuals aged 40 and over (8). Rates were similar in
men and women and increased with age (6).
The underlying pathophysiology of OAB has not
been completely explained, but includes abnormali-
ties in the detrusor muscle, whereby spontaneous
motor activity may occur, and the urothelium, which
can trigger urgency by neurotransmitter release and
by central mechanisms, linked to cerebral white
matter changes, particularly in the prefrontal regions
of the brain. The urothelium/suburothelium
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compartment of the bladder has a high metabolic
rate and is now believed to play a key role in me-
chanosensory transduction (9).
What is metabolic syndrome?
The metabolic syndrome (MetS) is a common disor-
der, which describes the frequent clustering of several
metabolic abnormalities, including central obesity,
dyslipidaemia, hypertension, insulin resistance and
glucose intolerance [Type 2 diabetes, impaired glucose
tolerance (IGT) or impaired fasting glycaemia] (10).
This combination of symptoms occurs in individuals
more often than might be expected by chance alone
(10), and when grouped together are associated with
increased risk of cardiovascular disease, including cor-
onary heart disease (CHD), stroke (11,12) and type 2
diabetes (13,14). In most cases, MetS is thought to
develop as a result of poor eating habits and a seden-
tary lifestyle; and with the current global epidemic of
obesity and diabetes the prevalence of MetS is growing
rapidly (10), adversely affecting daily activities and
general well-being (15). In addition to general obesity,
the distribution of body fat, in particular abdominal
obesity, is independently associated with the MetS in
older women, particularly among those of normal
body weight (16).
The World Health Organization developed the first
internationally accepted definition of MetS in 1998
(17); since then, other organisations have proposed
definitions, including the National Cholesterol Educa-
tion Program’s Adult Treatment Panel III Report (18),
The International Diabetes Federation (IDF; 19) and
the American Heart Association and the National
Heart, Lung and Blood Institutes (20). The varying
definitions (Table 1) all accept four core components
of MetS – glucose intolerance, obesity, hypertension
and dyslipidaemia – but differ in the specific levels set
for each component and the combination of symp-
toms required. For example, the IDF (19) puts more
emphasis on central obesity, as it is more strongly
related to other MetS features than any other factor (21).
The Metabolic Syndrome and LUTS
Recently, MetS has been implicated in the aetiology
of LUTS (22) and is thought to affect bladder func-
tion by its stimulating effects on the autonomic ner-
vous system (ANS). Evidence of an association
between MetS and OAB has been identified in
women (23,24). MetS may cause OAB symptoms via
a number of possible mechanisms. These include act-
ing through the ANS either directly or by induction
of diabetes and the production of pelvic ischaemia
via atherosclerosis (25).
Accumulating evidence from clinical studies and
basic research suggests that ischaemia may be an
independent factor in the development of non-
obstructed non-neurogenic bladder overactivity and
LUTS. A close correlation between pelvic ischaemia
and bladder overactivity has been documented in
elderly men and women (26–29). Recent research
has established a link between LUTS and the MetS
in men (30), providing a rationale for the present
review, which focuses on the relationship between
MetS and OAB in women. The overall aim of this
systematic review was to synthesise the interna-
tional literature to determine whether there is an
association between MetS and LUTS or OAB in
women.
Methods
Inclusion criteria
We included studies pertaining to the effect of MetS
on the presence of OAB or other LUTS in women.
MetS was defined as: a combination, or clustering, of
several metabolic abnormalities or risk factors,
including (i) central obesity, (ii) dyslipidaemia, (iii)
hypertension, (iv) insulin resistance with compensa-
tory hyperinsulinaemia and (v) glucose intolerance
(Type 2 diabetes, IGT, or impaired fasting glycaemia)
(10). As there are relatively few studies focusing spe-
cifically on MetS, we broadened our criteria to
include related components of MetS such as abdomi-
nal obesity, insulin resistance and hyperlipidaemia.
Although diabetes is also a risk factor for MetS, we
excluded studies focusing on diabetes on the basis
that these patients may also have neuropathy and
more frequent UTIs (31,32).
We used the International Continence Society def-
inition of OAB, which defines it as a symptom syn-
drome; characterised by urinary urgency, with or
without urgency incontinence, usually with increased
daytime frequency and nocturia (33). We also
included studies reporting urgency urinary inconti-
nence (UUI) or mixed urinary incontinence (MUI),
but excluded those only reporting stress urinary
incontinence (SUI) as this is not associated with
OAB. We also excluded studies where the type of
incontinence was not specified.
We included all studies that examined an associa-
tion between OAB and MetS in women. This
included cross-sectional studies, cohort studies and
case–control studies. Our main outcome of interest
was the association between OAB and MetS, but we
also looked at the association of other components
of MetS (such as abdominal obesity measured by
waist circumference) with OAB or urinary symptoms
associated with OAB such as urgency incontinence.
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Identification of studies
To identify studies for the review, we searched the
following electronic databases: PubMed, Web of
Science (including SCI, SSCI, HCI), Google Scholar
and the Cochrane Library. In addition, we used
‘lateral searching’ techniques such as checking ref-
erence lists of relevant papers, and using the ‘Cited
by’ option on Google Scholar and Scopus, and the
‘Related articles’ option on PubMed. Methodologi-
cal search filters were not used. Searches were lim-
ited to published English language studies. There
were no date restrictions. Database searches were
run in August 2012 and lateral searching was
updated in October 2013; search terms can be seen
in Box 1.
Study screening
Electronic search results were downloaded into End-
Note bibliographic software and, where possible,
duplicates deleted. Title and abstracts were screened
by one author with a random 10% of records inde-
pendently screened by a second author to check for
agreement. Full manuscripts of all potentially rele-
vant citations were screened independently by two
reviewers using a screening form with clearly defined
criteria. Uncertainties were resolved by consensus or
by discussion with a third reviewer.
Data extraction, critical appraisal and analysis
For studies that met the inclusion criteria, data were
extracted onto a predesigned, and piloted, form.
Data included the following: type of study design
(e.g. cross-sectional, case–control), characteristics of
participants (including age, sex, ethnicity), number
of participants, country of origin, outcomes relating
to MetS or OAB (including how they were mea-
sured) and estimation of association between MetS,
or components of MetS, and OAB.
The methodological quality of studies was assessed
using criteria based on those of the Centre for Evi-
dence Based Management. The core quality assessment
principles are summarised in Table 2. Owing to sub-
Table 1 Definitions of MetS
Organisation Definition of MetS
The American Heart
Association and
the National Heart
Lung and Blood
Institute criteria
for the MetS
(relevant to men)
Diagnosis of the MetS requires any three of the following:
• Waist circumference > 38 inches (88 cm)
• Blood pressure of 130 mmHg systolic OR 85 mmHg diastolic, or greater OR on antihypertensive
Medication
• HDL-C < 0.9 mmol/l OR drug treatment for reduced HDL-C
• Fasting triglycerides of 1.7 mmol/l or greater OR drug treatment for elevated triglycerides
• Fasting glucose of 5.6 mmol/l or greater OR drug treatment for elevated glucose
The WHO definition
of the MetS
Glucose intolerance, IGT or type 2 diabetes and/or insulin resistance together with two or more of the other
components listed below
• Impaired glucose regulation or diabetes
• Insulin resistance (under hyperinsulinaemic euglycaemic conditions, glucose uptake below lowest quartile
for background population under investigation)
• Raised arterial pressure ≥ 140/90 mmHg
• Raised plasma triglycerides (≥ 1.7 mmol/l; 150 mg/dl) and/or low HDL cholesterol
(< 0.9 mmol/l, 35 mg/dl men; < 1.0 mmol/l, 39 mg/dl women)
• Central obesity (men: waist to hip ratio > 0.90; women: waist to hip ratio > 0.85) and/or BMI > 30 kg/m2
• Microalbuminuria (urinary albumin excretion rate ≥ 20 lg/min or albumin:creatinine ratio (≥ 20 mg/g)
The new
International
Diabetes
Federation (IDF)
Must have central obesity plus any two of the following four factors
• Raised triglycerides ≥ 150 mg/dl (1.7 mmol/l) or specific treatment for this lipid abnormality
• Reduced HDL cholesterol < 40 mg/dl (1.03 mmol/l) in men, < 50 mg/dl (1.29 mmol/l) in women
• Raised blood pressure. Systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg
• Raised fasting plasma glucose FPG ≥ 100 mg/dl (5.6 mmol/l) or previously diagnosed type 2 diabetes
Box 1 Search terms
PubMed (terms were adapted for other databases)
((overactive bladder [MH] OR ‘bladder problems’ OR inconti-
nence OR ‘pelvic floor disorder’ OR urologic diseases [MH])
AND ‘metabolic syndrome’ OR insulin resistance [MH] OR dia-
betes [MH] OR hypertension [MH] OR ‘cardiovascular disease’
OR hyperlipidemia OR ‘polycystic ovary syndrome’) AND
Women* OR woman* OR female*[Title/Abstract] Filters:
Humans Filters: Humans
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stantial heterogeneity, studies were not pooled in a
meta-analysis, but are presented in a narrative and
tabular summary. Results are reported in the following
categories: (i) OAB and MetS; (ii) OAB and associated
components of MetS (e.g. obesity); (iii) UUI or MUI
and MetS; and (iv) UUI or MUI and associated com-
ponents of MetS. Where possible, data are reported as
relative risks with 95% confidence intervals.
Results
Description of studies
Twenty-nine papers reporting 27 studies met the
inclusion criteria (Table 3) (4,7,23,24,34–57). An
overview of the selection process can be seen in Fig-
ure 1. Two studies were classified as case–control
studies (24,46) and the rest as surveys/cross-sectional
studies. The number of participants in studies ranged
from 60 to 27,936.
Fifteen studies made a specific reference to OAB
(4,23,24,35,36,38,40,43–46,50–52,55,56). The others
categorised urinary symptoms in a variety of ways
including LUTS, UUI, SUI and MUI. Details of the
type of incontinence and how it was measured and
classified can be seen in Table 4.
Only four studies looked specifically at MetS
(23,40,42,43). Definitions of MetS were based on cri-
teria relating to waist circumference and levels of tri-
glycerides, high-density lipoprotein cholesterol, blood
pressure and fasting glucose. The remaining studies
included information about components of MetS
such as obesity, insulin resistance and dyslipidaemia.
Obesity was most commonly measured using the
body mass index (BMI; reported in 27 studies) but a
number of studies also looked at waist circumference
(reported in nine studies) or waist-hip ratio.
Study quality
Of the observational studies, 13 were judged to be free
from selection bias because they involved a popula-
tion-based sample or large samples from general prac-
tice or a HMO database. In seven studies, the response
rate was not clear, but of the others, 11 were judged to
have a satisfactory response rate (≥ 50%). Quality
assessment scores can be seen in Table 5 and a sum-
mary of quality assessment domains for the 25 cross-
sectional studies in Figure 2.
Findings
Three studies looked at the link between OAB and
MetS, 12 the link between OAB and associated risk
factors (such as obesity and hyperlipidaemia), three
the association between MetS and urinary symptoms
and 14 the link between UUI or MUI and compo-
nents of MetS. Details of the results (including effect
sizes) can be seen in Table 5.
Table 2 Core principles of study quality assessment
Study type
and tool used Scoring criteria
Surveys/cross-sectional
Scored as Yes, no, or
Can’t answer
1. Did the study address a clearly focused question/ issue?
2. Is the research method (study design) appropriate for answering the research question?
3. Is the method of selection of the subjects (employees, teams, division, organisations) clearly described?
4. Is the sample free from selection bias?
5. Was the sample representative with regard to the population to which the findings will be referred?
6. Was the sample size based on prestudy considerations of statistical power?
7. Was a satisfactory response rate achieved?
8. Are the measurements (questionnaires) likely to be valid and reliable?
9. Was the statistical significance assessed?
10. Are confidence intervals given for the main results?
Case–control study
Scored as Yes, no, or
Can’t answer
1. Did the study address a clearly focused question/ issue?
2. Is the research method (study design) appropriate for answering the research question?
3. Were there enough subjects in the study to establish that the findings did not occur by chance?
4. Was the selection of cases and controls based on external, objective and validated criteria?
5. Were both groups comparable at the start of the study?
6. Were objective and unbiased outcome criteria used?
7. Is there data dredging?
8. Are objective and validated measurement methods used to measure the outcome? If not, was the
outcome assessed by someone who was unaware of the group assignment?
9. Is the size effect practically relevant
10. How precise is the estimate of the effect? Were confidence intervals given?
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MetS and overactive bladder
Of the three studies that looked at whether there
appeared to be a link between OAB and MetS
(23,40,43), all found a significant association. How-
ever, these studies had relatively small sample sizes
and none scored more than six on the quality assess-
ment tool.
OAB and associated risk factors
Ten studies considered whether there was a link
between OAB and obesity. There was a statistically
significant link between obesity (as measured by
BMI) and OAB in eight (4,23,35,36,44–46,51),
although in one small study (35), this was only
significant in premenopausal women. Four of the
studies that found a positive correlation had a
quality assessment score of 8 or above. Of the oth-
ers, one found a non-significant trend towards
increasing prevalence of OAB with higher degree of
obesity (55) and one (24) no significant association
between OAB and BMI. Two studies found
increasing odds of OAB in those with an increased
waist circumference (23,45) and another reported
no significant association between OAB and waist
circumference (24). Four studies looked at the link
between hyperlipidaemia and OAB; three found no
significant association (23,24,38) and one found
increased odds of OAB in those with hyperlipida-
emia (56).
MetS and urinary symptoms (LUTS, urgency,
frequency)
Of the three studies that examined the link between
MetS and urinary symptoms (40,42,52), one (52)
found a possible association, one (40) a significant
difference in LUTS scores in those with MetS and
one an association between MetS and MUI but not
UUI (42).
Urinary symptoms (e.g. LUTS, UUI) and
associated risk factors
Ten studies found an increased likelihood of urinary
symptoms in those who were obese, but four did not
(7,38,40,48). Of those that did find an association
Figure 1 Flow chart of study selection process
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Table 4 Type of incontinence and method of measurement
Study ID
Type of incontinence
OAB/LUTS/UUI/SUI/mixed Method of classification/measurement
Brown et al. (1999) UUI, SUI, MUI Variety of questions relating to voiding and incontinence
UUI – have you unintentionally leaked some urine before you could get to the bathroom?
Cheung et al. (2009) OAB, LUTS (including
SUI, UI and MUI)
Overactive Bladder-Validated 8-question Screener (OAV-V8). OAB defined as an OAB-V8 score
equal to or greater than 8
de Boer et al. (2011) OAB Urinary Distress Inventory (UDI). Symptoms were dichotomised. If symptoms denied/ not
bothered = no (absent). If present and little to severely bothered = yes (present)
Elia et al. (2001) UUI, SUI Urgency – strong desire to void accompanied by fear of leakage or pain
Frequency – voiding more often than every 2 h or more than six times during daytime
Garnica et al. (2011)
Stewart & Minassian (2010)
OAB Bladder health survey – used questions relating to urgency and UI. OAB is defined as a
composite score of 5 + (range, 0–12)
Gokkaya et al. (2013) LUTS Turkish validated versions of the International Prostate Symptom Score (IPSS) and Bristol
Female Lower Urinary Tract Symptoms (BFLUTS)
Hannestad et al. (2003) UUI, SUI, Mixed Sandvik severity index
Hall et al. (2008) SUI, UUI 14 non-pain-related urological questions (similar to those in EPIC study)
Hong et al. (2010) LUTS, OAB IPSS (International prostate symptom score) and OABq-SF (Overactive Bladder Questionnaire
Short Form)
Jackson et al. (2004) UUI, SUI Questions adapted from previous studies. Question – in the past 12 months have you leaked
even a small amount of urine? And In the past 12 months, how often have you leaked urine?
Classified as UIU –the urge to urinate and can’t get to a toilet fast enough
Kim et al. (2011) MUI Pelvic Floor Distress Inventory-20 (PFDI-20) including the Urinary Distress Inventory-6 (UDI-6).
Analysis focused on Q. 16 and 17 for urgency and stress UI
Kinjo et al. (2009) OAB Overactive bladder symptom score (OABSS) and International consultation of incontinence
questionnaire (ICIQ-SF)
Khullar et al. (2013) UUI, SUI, MUI LUTS tool
Lawrence et al. (2007) OAB Epidemiology of prolapse and incontinence questionnaire (EPIQ)
Based on responses to stem questions and degree of bother
Link et al. (2011) OAB OAB defined as urinary frequency, and urgency or urge leakage
Frequency: < every 2 h, rated ‘fairly often, usually, almost always’ or > 8 times daily.
Urgency: difficulty postponing, strong urge in the last month or week (four times). Urgency
leakage: 1 or more occasions of accidental in the last week
McGrother et al. (2006) OAB, SUI OAB defined as urgency leakage or urgency – occurring monthly or more
Melin et al. (2007) OAB, LUTS Short-form Incontinence Impact Questionnaire (IIQ-7) and Urogenital Distress Inventory (UDI)
Mommsen (1994) UUI, SUI, MUI Question – have you experienced episodes of UI?, Urge – defined as feeling of urge to void
Peyrat (2002) UUI, SUI, MUI Question – do you currently have some involuntary leakage of urine?
Urge – defined as involuntary loss of urine preceded by a sensation of urgency or by rapid
and uncontrollable voiding with little or no warning
Schwartz et al. (2009) SUI, UUI Questions adapted from several validated questionnaires including BFLUTS
Teleman et al. (2004) OAB, MUI BFLUTS
Townsend et al. (2007) SUI, UUI, MUI Sandvik Severity Index
Uzum & Zorba (2012a) OAB, LUTS OAB validated 8 question screener. Score of 8 or less needed for OAB diagnosis
Uzum & Zorba (2012b) OAB International Continence Society 2010 definition of OAB
OAB-OAB validated 8 question screener. Score of 8 or less needed for OAB diagnosis
Waetjen et al. (2007) UUI, SUI Question – in past year have you ever leaked even a small amount of urine involuntarily? Urge
– urge to void and can’t reach toilet fast enough
Whitcomb et al. (2009) OAB, SUI EQIP Prolapse and Incontinence Questionnaire (includes questions relating to POP, SUI, OAB,
AI)
Yu et al. (2006) OAB International Continence Society 2010 definition of OAB
Structured questionnaire to collect info on LUTS (symptom frequency assessed on scale similar
to that used in American Urological Association Symptom Index
LUTS, lower urinary tract symptoms; MUI, mixed urinary incontinence; OAB, overactive bladder; SUI, stress urinary incontinence; UUI, urgency urinary incontinence.
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between urinary symptoms and increased BMI, eight
reported an increase in MUI (34,39,41,47,49,53,54,57).
One study (40) reported no significant correlation
between levels of high-density lipoproteins (HDL) and
International Prostate Symptom Score.
Discussion
We included 27 studies, but, of those, only three
looked specifically at the link between MetS and
OAB in women. The remaining literature evaluated
the links between OAB and components of MetS
such as obesity or insulin resistance (n = 10),
between MetS and urinary symptoms (n = 3) and
between urinary symptoms and components of MetS
(n = 14). Although the evidence is currently limited,
it does suggest that there may be important links
between MetS and OAB and between MetS and OAB
symptom complex.
Several studies have demonstrated strong links
between MetS and OAB in men (30,58,59). OAB has
also been reported to be significantly associated with
an increased prevalence of erectile dysfunction (ED)
in men (60,61) and ED has been reported to be
strongly related to MetS (62). Possible common
explanatory aetiological mechanisms include athero-
sclerotic vascular disease, decreased nitric oxide levels
or nitric oxide synthase expression and alterations of
calcium regulatory proteins in smooth muscle, all of
which influence both bladder and penile physiology.
Although the anatomy and pathophysiology in rela-
tion to obstruction and OAB symptoms are clearly
different in men and women, the underlying bladder
pathophysiology may share some common features.
An association between OAB and decreased sexual
enjoyment in women mediated via decreased clitoral
swelling, similar to ED in men, has also been
reported (60). In both sexes, changes in bladder
function may relate to changes in the bladder vascu-
lature, epithelium, neuronal supply, smooth muscle
and connective tissue, leading to LUTS. In older
women, LUTS questionnaire scores show similar
results to those of age-matched men (63,64).
There are a number of reported reasons why
women with MetS may be at greater risk of develop-
ing OAB. These include inflammatory sympathetic
overactivity, pro-inflammatory status, oxidative stress
and endothelial dysfunction in addition to ischaemic
damage during bladder storage, decreased perfusion
of the bladder and bladder neck, an increase in non-
esterified fatty acids and a nitric oxide deficiency.
OAB may result from pathological change in all lay-
ers of bladder wall, rather than just the smooth mus-
cle (myogenic theory) or nerves (neurogenic theory)
(23). OAB is associated with impaired bladder con-
tractility, in contrast to normal ageing, in addition to
an overactivity (65).
Insulin resistance caused by obesity is a significant
component of MetS and it is argued that pro-inflam-
matory state, increased free fatty acids, hypercoagula-
bility, and cellular oxidative stress lead to premature
vascular disease (66). In one study investigating this,
there was a positive correlation with serum insulin
levels in women with OAB. In addition, HOMA-IR,
a measure of insulin resistance, was significantly
higher in the OAB group in comparison to controls.
HDL cholesterol levels were significantly lower in
women with OAB (24).
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Clearly focused question
Appropriate research method
Selection of participants clearly described?
Free from selection bias?
Sample representative?
Sample based on power calculation?
Satisfactory response rate?
Measurements valid & reliable?
Statistical significance assessed?
Confidence intervals given?
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Figure 2 Summary of quality assessment domains for cross-sectional studies
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Additionally, an epidemiological survey (67) dem-
onstrated an association between increasing C-reac-
tive protein, a marker of inflammation, and OAB for
both men and women. An association with reduced
blood flow to the bladder and LUTS in older women
has also been demonstrated (26). Many women with
polycystic ovary syndrome have bladder storage
symptoms and additional features of the MetS, espe-
cially insulin resistance, obesity, and a raised serum
testosterone concentration. These women have a
higher prevalence and a greater degree of hyperinsu-
linaemia (68,69); as many as 30% have IGT and
7.5% have diabetes, (70) leading to increased cardio-
vascular risk (71). Because the ovarian hyperandroge-
nism contributes to insulin resistance (72), it may be
contributing to the bladder storage symptoms in
these women (73).
Limitations
We used systematic and rigorous methods to syn-
thesise the current evidence on the link between
OAB and MetS in women. However, there are a
number of methodological limitations that could
have a bearing on the validity of the results. We
found only three studies that looked specifically at
the association of OAB and MetS; other studies
looked at components of MetS (such as obesity) or
urinary symptoms more generally (e.g. LUTS). In
addition, the quality of the studies was mixed with
none of the studies fulfilling all of the criteria on the
quality assessment checklists.
Implications for practice
The evidence supporting links between the MetS and
LUTS in women is weaker than in men. However,
current evidence does suggest that in women present-
ing with OAB, consideration should be given to
whether the MetS is present. Although it is not
known whether reducing insulin resistance and obes-
ity related chronic inflammation and oxidative stress
might prevent the onset of OAB and reduce LUTS,
identifying women with MetS provides an opportu-
nity to address the portfolio of cardiovascular risk
factors and prevent premature morbidity and mortal-
ity. Although it remains prudent to recommend
weight loss in overweight and obese women, control
of all modifiable cardio-metabolic risk factors in both
normal and overweight persons to prevent transition
to the MetS and diabetes should be considered the
ultimate goal (74).
Obesity and type 2 diabetes are particularly detri-
mental to women’s health. Women with a higher
degree of abdominal obesity are especially susceptible
to type 2 diabetes, and women with diabetes have a
disproportionally higher relative risk of CHD than
men with diabetes (75,76). As the MetS may be a
better predictor of future cardiovascular risk in
women than the BMI, waist circumference may be a
more important clinical measure than the BMI. Key
variables to explore are diet and lifestyle, especially
exercise routines, lipids, blood pressure and dysglyca-
emia. Investigations should include a blood pressure
recording, BMI and waist circumference measure-
ment together with a lipid profile and HbA1c. These
results should be transmitted to the Primary Health-
care Team for action.
Conclusions
There is increasing evidence to suggest there may be
a link between MetS and OAB or LUTS. There is
good evidence to suggest that obesity is an important
predictor of LUTS in women. Many obese women
will have features of the MetS, if looked for, and this
provides a window of opportunity to address cardio-
vascular risk factors and prevent future cardiovascu-
lar morbidity and mortality; the effect of
intervention on LUTS in women is unclear.
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